Joe Nagamizo

Joe received his B.S. and M.S. degrees in Chemistry from UC San Diego. Prior to joining Genesis, he was part of the medicinal chemistry team at Inception Sciences for six years working on a variety of different targets. He has contributed to multiple patents, which include a dual EP2/4 antagonist currently undergoing Phase I clinical trials.